Martin Shkreli’s journey from pharma exec to inmate No. 87850-053

Martin Shkreli burst on the scene as an enfant terrible, a securities savant who was working on Wall Street at 17, set up his own hedge fund at 23, and launched the biotech company Retrophin Inc. after teaching himself biology.

Some may remember him as the trader who shorted drug companies after…